TD Private Client Wealth LLC Has $625,000 Stock Holdings in Humana Inc. (NYSE:HUM)

TD Private Client Wealth LLC lifted its holdings in shares of Humana Inc. (NYSE:HUM) by 16.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,464 shares of the insurance provider’s stock after purchasing an additional 346 shares during the period. TD Private Client Wealth LLC’s holdings in Humana were worth $625,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Pzena Investment Management LLC boosted its stake in shares of Humana by 44.0% in the 4th quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider’s stock valued at $915,736,000 after purchasing an additional 1,103,132 shares during the last quarter. Boston Partners lifted its stake in shares of Humana by 435.8% in the fourth quarter. Boston Partners now owns 1,098,702 shares of the insurance provider’s stock valued at $279,236,000 after buying an additional 893,637 shares in the last quarter. FMR LLC boosted its stake in Humana by 23.4% during the 3rd quarter. FMR LLC now owns 3,388,859 shares of the insurance provider’s stock valued at $1,073,387,000 after purchasing an additional 643,291 shares during the last quarter. Retirement Systems of Alabama boosted its position in shares of Humana by 735.9% during the fourth quarter. Retirement Systems of Alabama now owns 219,002 shares of the insurance provider’s stock valued at $55,563,000 after buying an additional 192,801 shares during the last quarter. Finally, Worldquant Millennium Advisors LLC purchased a new position in Humana during the 3rd quarter worth $50,102,000. 92.38% of the stock is owned by institutional investors and hedge funds.

Humana Stock Performance

NYSE:HUM opened at $266.33 on Monday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76. Humana Inc. has a fifty-two week low of $213.31 and a fifty-two week high of $406.46. The firm has a market cap of $32.14 billion, a PE ratio of 26.77, a price-to-earnings-growth ratio of 2.05 and a beta of 0.57. The business has a 50 day moving average price of $271.33 and a 200-day moving average price of $276.25.

Humana (NYSE:HUM) last announced its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. Equities research analysts predict that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be given a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a dividend yield of 1.33%. The ex-dividend date is Friday, March 28th. Humana’s dividend payout ratio is currently 35.58%.

Insiders Place Their Bets

In related news, insider Timothy S. Huval sold 3,703 shares of the stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the transaction, the insider now directly owns 8,181 shares in the company, valued at $2,096,463.06. This trade represents a 31.16 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.37% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Cantor Fitzgerald restated a “neutral” rating and issued a $290.00 target price on shares of Humana in a research note on Wednesday, February 12th. Piper Sandler increased their target price on shares of Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 15th. StockNews.com cut Humana from a “buy” rating to a “hold” rating in a research report on Tuesday, March 18th. Barclays boosted their price objective on shares of Humana from $255.00 to $270.00 and gave the company an “equal weight” rating in a research note on Thursday, February 13th. Finally, Truist Financial upped their target price on Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a research note on Monday, January 6th. Eighteen analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, Humana has an average rating of “Hold” and a consensus target price of $285.68.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.